The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | KEYMAKER-U06 substudy 06A: favezelimab or MK-4380 in esophageal cancer
Ken Kato, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, describes the trial design and rationale of the Phase I/II KEYMAKER-U06: Substudy 06A trial (NCT05342636) of investigational agents with pembrolizumab, plus chemotherapy (irinotecan or paclitaxel), MK-4830, an anti-ILT4 antibody, or lenvatinib in pre-treated patients with advanced esophageal cancer. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
